Barrett's esophagus: Surveillance and treatment

Gastroenterology Clinics of North America

Volumn 31, Issue 2, 2002, Pages 481-497

  Katzka, David A ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; ANTIULCER AGENT;

AGE; BARRETT ESOPHAGUS; DISEASE ASSOCIATION; DYSPLASIA; ENDOSCOPY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HUMAN; MEDICAL DECISION MAKING; REVIEW; SCREENING; SURGICAL RISK; CELL TRANSFORMATION; ELECTROCOAGULATION; ESOPHAGUS TUMOR; GASTROESOPHAGEAL REFLUX; HEALTH SURVEY; METAPLASIA; METHODOLOGY; PATHOLOGY; PRECANCER; SURVIVAL RATE; UNITED STATES;

ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; ELECTROCOAGULATION; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HUMAN; METAPLASIA; POPULATION SURVEILLANCE; PRECANCEROUS CONDITIONS; SURVIVAL RATE; UNITED STATES; HUMANS;

EID: 0035992165     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8553(02)00020-1     Document Type: Review

References (56)

1. Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in Barrett's esophagus
2. Complete elmination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus
3. Long-term results of classic antireflux surgery in 152 patients with Barrett's esophagus: Clinical, radiologic, endoscopic manometric, and acid reflux test analysis before and late after operation
4. Dynamic effects of acid on Barrett's esophagus
5. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression
6. Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus
7. Conservative treatment versus antireflux surgery in Barrett's esophagus
8. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus
9. Regression of columnar lined (Barrett's) esophagus with continuous omeprazole therapy
10. Partial regression of Barrettt's esophagus by long-term therapy with high-dose omeprazole
11. Prospective multivariate analysis of fractors predictive of complete regression of Barrett's esophagus
12. Endoscopic regression of Barrett's esophagus during omeprazole treatment: A randomized double blind study
13. Ranitadine controls nocturnal acid breakthrough on omeprazole: A controlled study in normal subjects
14. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose aneprazole
15. Bile reflux in columnar-lined Barrett's esophagus
16. Mixed reflux of gastric and duodenal juice is more harmful to the esophagus than gastric juice alone
17. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy
18. Role of reflux esophagitis and acid in the development of columnar epithelium in the rat esophagus
19. Epithelial cell hyperproliferation after biliopancreatic reflux into the esophagus of rats
20. Duodenogastroesophageal reflux: Relationship to pH and importance in Barrett's esophagus
21. Effects of omeprazole 20 mg twice daily on duodenogastric and gastroesophageal bile reflux in Barrett's esophagus
22. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy
23. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease. Follow-up of a randomized controlled trial
24. Endoscopic surveillance of Barrett's esophagus. Does it help?
25. Outcome of adenocarcinoma arising in Barrett's esohagus in endoscopically surveyed and non-surveyed patients
26. Impact of endoscopic biopsy surveillance of Barrett's esophagus on pathological stage and clinical outcome of Barrett's carcinoma
27. Is there publication bias in the reporting of cancer risk in Barrett's esophagus
28. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus
29. A guide for surveillance of patients with Barrett's esophagus
30. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: Comparison with traditional long segment Barrett's esophagus
31. Dysplasia in short-segment Barrett's esophagus: A propsective 3-year follow-up
32. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: Prevalence and clinical data
33. Observer variation in the diagnosis of dysplasia in Barrett's esophagus
34. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: A reaffirmation
35. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort
36. Dysplasia as a predictor marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study
37. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia
38. Esophageal cancer is an uncommon cause of death in patients with Barrett's esophagus
39. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma
40. Role of endoscopic ultrasound in patients with Barrett's esophagus and high grade dysplagia
41. Is endoscopic ultrasonography (EUS) cost effective to screen for cancer in patients with Barrett's esophagus (BE)?
42. Endosonography in the evaluation of patients with Barrett's esophagus and HGD
43. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole
44. Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation
45. Biomarker studies in reversed Barrett's esophagus
46. Photodynamic therapy for Barrett's esophagus: Follow-up on 100 patients
47. Photodynamic ablation of high grade dysplasia and early cancer in Barrett's esophagus by means of 5 aminolevulinic acid
48. Long-term results of photodynamic therapy for Barrett's esophagus
49. The histopathology of treated Barrett's esophagus: Squamous reepithelialization after acid suppression and laser and photodynamic therapy
50. Current status of photodynamic therapy of Barrett's esophagus
51. Eradication of high grade dysplasia in columnar lined (Barrett's) esophagus by photodynamic therapy with endogenously generated protophorphyrin IX
52. Fate of high grade dysplasia at 1 year after endoscopic albation with Nd:Yag laser and electrocautery
53. Initial results using low-dose photodynamic therapy in the treatment of Barrett's esophagus
54. Adenocarcinoma arising in columnar lined esophagus following treatment with argon plasma coagulation
55. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy
56. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus